This is the first in a series of articles in our Newsletters on pricing and reimbursement in the European Union.
This article deals with the basic principles for pricing of medicinal products in the UK under the:
- voluntary scheme established by Pharmaceutical Price Regulation Scheme (PPRS); and
- statutory scheme established by the Health Service Branded Medicines (Control of Prices and Supply of Information) (No.2) Regulations 2008 and the Health Service Medicines (Information Relating to Sales of Branded Medicines etc.) Regulations 2007 as amended by the Health Service Medicines (Control of Prices and Supply of Information) (Amendment) Regulations 2013 (that came into force 1 January 2014) and Health Service Medicines (Control of Prices and Supply of Information) (Amendment) Regulations 2015 (that came into force 9 March 2015) (statutory scheme).
These schemes were established under the National Health Service Act 2006 that gives the UK government power to limit the prices of and profits to be delivered from medicines sold to the UK’s National Health Service (NHS).
This article also briefly deals with the role of The National Institute for Health and Care Excellence (NICE) in relation to the availability and pricing of medicinal products in the UK, pricing arrangements as well as the use of reference pricing in the EU.
Source: Eversheds LLP – Brett Rowland – Lexology